DVA Jan 2024 87.500 call
| Previous Close | 10.84 |
| Open | 10.84 |
| Bid | 15.30 |
| Ask | 17.60 |
| Strike | 87.50 |
| Expire Date | 2024-01-19 |
| Day's Range | 10.84 - 10.84 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 11 |
ZacksMedtronic (MDT) to Expand Diabetes Care With New Buyout
Medtronic's (MDT) latest acquisition will increase its capacity to assist more individuals with diabetes worldwide within a single, seamless Medtronic support ecosystem.
ZacksHere's Why You Should Retain CVS Health (CVS) Stock for Now
Investors are optimistic about CVS Health (CVS) on continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services.
ZacksThermo Fisher (TMO) Expands Manufacturing Facility in APAC
Thermo Fisher (TMO) latest expansion will enable it to better assist clients in accelerating their research, development and marketing of medications and vaccines in the Asia-Pacific region.
ZacksHere's Why Investors Should Add Zimmer Biomet (ZBH) Now
Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.
ZacksQIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory
QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.
- Zacks
National Vision (EYE) Plans to Open New Stores Amid Macro Woes
National Vision (EYE) plans to continue executing core growth initiatives and further investing in competitive advantages.
ZacksAbbott (ABT) Expands in Electrophysiology With New FDA Nod
Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.
ZacksHologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test
Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.
ZacksAbbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval
Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.
ZacksWhat's in the Cards for Medtronic (MDT) in Q4 Earnings?
Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.
- Zacks
STERIS (STE) Continues to Face Dull Dental Sales, Margin Woes
STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.
ZacksVeeva Systems' (VEEV) New Launch to Improve Patient Outcomes
Veeva Systems' (VEEV) new offering is expected to facilitate effective engagement with customers and KOLs for improved patient journeys.
ZacksEdwards Lifesciences' (EW) TAVR Study Outcome Favorable
Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.
ZacksHere's Why Investors Should Retain Omnicell (OMCL) Stock Now
Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.
ZacksBD's (BDX) New FDA Approval to Improve MRSA Diagnostics
BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.
ZacksMedtronic's (MDT) Global Market Share Strong, FX Headwind Stays
Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.
ZacksLabCorp (LH) Expands Laboratory Relationship With New Pact
LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.
ZacksNextGen (NXGN) Q4 Earnings Top Estimates, Revenues Surge Y/Y
NextGen's (NXGN) fourth-quarter fiscal 2023 results reflect strength in both its revenue sources.
Zacks3 Reasons to Retain Masimo (MASI) Stock in Your Portfolio
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Simply Wall St.DaVita Inc.'s (NYSE:DVA) Intrinsic Value Is Potentially 50% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, DaVita fair value estimate is US$148 DaVita is estimated to be...
ZacksShockwave Medical (SWAV) Launches IVL Catheter in Select Markets
Shockwave Medical's (SWAV) latest commercial availability and the patient enrollment in its study are expected to serve a wider patient pool.
- Thomson Reuters StreetEvents
Q1 2023 Cara Therapeutics Inc Earnings Call
Q1 2023 Cara Therapeutics Inc Earnings Call
ZacksEarnings Estimates Rising for DaVita HealthCare (DVA): Will It Gain?
DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks2 Top-Rated Medical Stocks to Buy After Earnings
As we round out this week's earnings lineup, a few healthcare companies are standing out after topping their quarterly earnings expectations.
ZacksIs Addus HomeCare (ADUS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
